NYSE:ELANElanco Animal Health Stock Price, Forecast & News

Elanco Animal Health's stock was trading at $23.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ELAN stock has decreased by 7.1% and is now trading at $22.03. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Elanco Animal Health.

Elanco Animal Health is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Elanco Animal Health.

Elanco Animal Health will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings results on Thursday, May, 7th. The company reported $0.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.24 by $0.11. The business had revenue of $657.70 million for the quarter, compared to the consensus estimate of $720.19 million. Elanco Animal Health had a positive return on equity of 6.10% and a negative net margin of 0.42%. The company's revenue for the quarter was down 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.25 EPS. View Elanco Animal Health's earnings history.

10 brokers have issued 1 year price objectives for Elanco Animal Health's stock. Their forecasts range from $25.00 to $34.00. On average, they expect Elanco Animal Health's stock price to reach $29.20 in the next year. This suggests a possible upside of 32.5% from the stock's current price. View analysts' price targets for Elanco Animal Health.

Media stories about ELAN stock have trended very negative this week, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Elanco Animal Health earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Elanco Animal Health.

Some companies that are related to Elanco Animal Health include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS) and GALAPAGOS NV/S (GLPG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), Walt Disney (DIS), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Home Depot (HD) and Pfizer (PFE).

(ELAN) raised $1.4 billion in an initial public offering on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

Elanco Animal Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.09%), Envestnet Asset Management Inc. (0.08%), State of Alaska Department of Revenue (0.02%), West Oak Capital LLC (0.02%), Addenda Capital Inc. (0.02%) and DNB Asset Management AS (0.02%). Company insiders that own Elanco Animal Health stock include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View institutional ownership trends for Elanco Animal Health.

ELAN stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Sanders Morris Harris LLC, Addenda Capital Inc., DNB Asset Management AS, West Oak Capital LLC, and State of Alaska Department of Revenue. Company insiders that have bought Elanco Animal Health stock in the last two years include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral, and Todd S Young. View insider buying and selling activity for Elanco Animal Health.

Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ELAN stock can currently be purchased for approximately $22.03.

Elanco Animal Health has a market capitalization of $8.79 billion and generates $3.07 billion in revenue each year. The company earns $67.90 million in net income (profit) each year or $1.06 on an earnings per share basis. Elanco Animal Health employs 6,080 workers across the globe.

The official website for Elanco Animal Health is www.elanco.com.

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261.